Octreotide inhibits increases in short-circuit current induced in rat colon by VIP, substance P, serotonin and

J E Fassler1, T M O'Dorisio, H S Mekhjian

  • 1Department of Internal Medicine, Ohio State University, Columbus.

Regulatory Peptides
|July 30, 1990
PubMed

Insights

Octreotide (OCT), a somatostatin analog, inhibits intestinal secretion by affecting short-circuit current (Isc). OCT reduces responses to VIP, serotonin, and substance P, indicating multiple inhibitory mechanisms.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Physiology

Background:

  • Vasoactive intestinal peptide (VIP), aminophylline, serotonin (5-HT), and substance P are key regulators of intestinal secretion.
  • Octreotide (OCT), a somatostatin analog, is known to modulate various physiological processes.

Purpose of the Study:

  • To investigate the effect of OCT on short-circuit current (Isc) in rat colon.
  • To determine OCT's impact on intestinal secretory responses induced by specific secretagogues.

Main Methods:

  • Measurement of short-circuit current (Isc) in rat colon tissues.
  • Administration of OCT at varying concentrations.
  • Stimulation of tissues with VIP, aminophylline, 5-HT, and substance P.

Main Results:

  • OCT significantly decreased basal Isc, with maximum effect at 10(-6) M.
  • OCT inhibited intestinal secretory responses to VIP, 5-HT, and substance P.
  • OCT shifted the aminophylline concentration-response curve but did not reduce the maximum response.

Conclusions:

  • OCT inhibits intestinal secretion through multiple mechanisms.
  • OCT affects both cAMP-dependent and calcium-linked pathways involved in intestinal secretion.

Related Concept Videos

Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...